Gai RY, Qu XJ, Lou HX, Han JX, Cui SX, Nakata M, Kokudo N, Sugawara Y, Kuroiwa C, Tang W. GMP implementation in China: A double-edged sword for the pharmaceutical industry.
Drug Discov Ther 2007;
1:12-13. [PMID:
22504359]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
China's Good Manufacturing Practice (GMP) standards that mainly parallel WHO standards were made compulsory in 2004. However, GMP implementation had both positive as well as negative impacts on the pharmaceutical industry, with negatives including pharmaceutical companies suffering economic hardships, poor execution of GMP standards, and sequent health scares. This report briefly describes the problems with GMP implementation in China.
Collapse